Misplaced Pages

Stiff-person syndrome: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 05:08, 5 January 2006 editUthbrian (talk | contribs)Extended confirmed users, Pending changes reviewers4,354 editsm add cat← Previous edit Revision as of 17:28, 2 February 2006 edit undoWouterstomp (talk | contribs)Administrators19,999 edits References: added reviewNext edit →
Line 4: Line 4:


==References== ==References==
{{note|mws}} {{Journal reference | Author=MOERSCH FP, WOLTMAN HW | Title=Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. | Journal=Mayo Clin Proc | Year=1956 | Pages=421-7 | Volume=31 | Issue=15 }} PMID 13350379 * {{note|mws}} {{Journal reference | Author=MOERSCH FP, WOLTMAN HW | Title=Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome); report of a case and some observations in 13 other cases. | Journal=Mayo Clin Proc | Year=1956 | Pages=421-7 | Volume=31 | Issue=15 }} PMID 13350379
* {{Journal reference issue | Author=Murinson BB | Title=Stiff-person syndrome | Journal=Neurologist | Year=2004 | Pages=131-7 | Volume=10 | Issue=3 }} PMID 15140273


] ]

Revision as of 17:28, 2 February 2006

First described by Moersch and Woltman at the Mayo Clinic in 1956, stiff person syndrome (SPS) is a rare neurologic disorder of unknown etiology. Those with the illness experience progressive, fluctuating tonic contractions of all muscles, particularly the axial musculature. Inability to walk and paralysis quickly ensues; death usually occurs six to twelve months after diagnosis.

Treatment is mostly palliative with muscle relaxants such as benzodiazepines, which lose their effectiveness as the illness progresses. Because many patients with SPS have circulating antibodies to glutamic acid decarboxylase, an autoimmune genesis to the disease has been postulated. In the absence of double-blind, placebo-controlled class A trials to determine treatment efficacy, some authorities recommend humane trials of immunosuppressive therapy, plasmapheresis or intravenous immunoglobulin infusion.

References

Categories: